Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/s13063-020-04731-2.

Title:
TREAT Early Arthralgia to Reverse or Limit Impending Exacerbation to Rheumatoid arthritis (TREAT EARLIER): a randomized, double-blind, placebo-controlled clinical trial protocol | Trials
Description:
Background We present a study protocol for a randomized, double-blind, placebo-controlled trial that investigates the hypothesis if intervention in the symptomatic phase preceding clinical arthritis (clinically suspect arthralgia (CSA)) is effective in preventing progression from subclinical inflammation to clinically apparent persistent arthritis. Currently, rheumatoid arthritis (RA) can be recognized and diagnosed when arthritis (joint swelling) has become detectable at physical examination. Importantly, at this time, the immune processes have already matured, chronicity is established, and patients require long-standing treatment with disease-modifying anti-rheumatic drugs. The TREAT EARLIER trial studies the hypothesis that intervention in the symptomatic phase preceding clinical arthritis is more often successful in permanent disease modification because of less matured underlying disease processes. Methods A two-level definition to identify patients that are prone to develop RA is used. First, patients should have CSA and recent-onset arthralgia (< 1 year) that is suspect to progress to RA according to the expertise of the treating rheumatologist. Second, patients need to have subclinical inflammation of the hand or foot joints at 1.5 T MRI. The trial aims to recruit 230 participants from secondary care hospital settings across the south-west region of The Netherlands. Intervention will be randomly assigned and includes a single-dose of intramuscular 120 mg methylprednisolon followed by methotrexate (increasing dose to 25 mg/week orally) or placebo (both; injection and tablets) over the course of 1 year. Thereafter, participants are followed for another year. The primary endpoint is the development of clinically detectable arthritis, either fulfilling the 2010 criteria for RA or unclassified clinical arthritis of ≥ 2 joints, which persists for at least 2 weeks. DMARD-free status is a co-primary endpoint. The patient-reported outcomes functioning, along with workability and symptoms, are key secondary endpoints. Participants, caregivers (including those assessing the endpoints), and scientific staff are all blinded to the group assignment. Discussion This proof-of-concept study is the logical consequence of pre-work on the identification of patients with CSA with MRI-detected subclinical joint inflammation. It will test the hypothesis whether intervention in patients in this early phase with the cornerstone treatment of classified RA (methotrexate) hampers the development of persistent RA and reduce the disease burden of RA. Trial registration Dutch Trial Register NL4599 (NTR4853). Registered on 20 October 2014
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Health & Fitness
  • Education
  • Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

arthritis, trial, patients, study, participants, data, article, mri, clinical, pubmed, google, scholar, rheumatoid, van, csa, mtx, inflammation, endpoint, rheumatology, arthralgia, primary, disease, protocol, treatment, rheum, subclinical, clinically, joints, ann, dis, department, lumc, phase, joint, netherlands, months, time, rheumatologists, results, participant, followup, early, development, risk, years, medical, cas, symptoms, mil, intervention,

Topics {✒️}

nl/richtlijnen/nvr-richtlijnen-standpunten-en-zorgpaden/ org/standaarden/volledig/nhg-standaard-artritis disease-modifying anti-rheumatic drugs van der horst-bruinsma steroidal anti-inflammatory drugs anti-citrullinated peptide antibody placebo-controlled trials aiming age-matched symptom-free persons anti-carbamylated protein antibodies van steenbergen hw article download pdf van nies ja joint/bone/tendon sheath level van der kooij placebo-controlled intervention study multiple joints/bones/tendon sheaths open-label dmard therapy participant open-ended questions randomized placebo-controlled mri-detected subclinical inflammation acute bone stress symptomatic pre-arthritis phase maturing auto-antibody response imaging-detected subclinical inflammation rheumatism eq-5d-5l acute-phase reactants achieve secondary prevention age-matched general population van de laar placebo-controlled trial received concomitant medication disease-modifying drugs bmc musculoskelet disord c-reactive protein van baarsen lg van dijk bt van gaalen fa gillet-van dongen ra-specific inflammation starts shared decision-making healthcare central committee achieved dmard-free status privacy choices/manage cookies ten brinck rm cyclic citrullinated peptide longitudinal leiden-csa cohort checking medical forms informed written consent—randomization clinically apparent arthritis open access reported

Questions {❓}

  • Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?
  • Is anti-citrullinated protein antibody-positive rheumatoid arthritis still a more severe disease than anti-citrullinated protein antibody-negative rheumatoid arthritis?
  • Rheumatoid arthritis prevention in arthralgia: fantasy or reality?
  • The earlier, the better or the worse?
  • What is the prevalence of MRI-detected inflammation and erosions in small joints in the general population?
  • Which patients presenting with arthralgia eventually develop rheumatoid arthritis?
  • Who will take informed consent?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:TREAT Early Arthralgia to Reverse or Limit Impending Exacerbation to Rheumatoid arthritis (TREAT EARLIER): a randomized, double-blind, placebo-controlled clinical trial protocol
         description:We present a study protocol for a randomized, double-blind, placebo-controlled trial that investigates the hypothesis if intervention in the symptomatic phase preceding clinical arthritis (clinically suspect arthralgia (CSA)) is effective in preventing progression from subclinical inflammation to clinically apparent persistent arthritis. Currently, rheumatoid arthritis (RA) can be recognized and diagnosed when arthritis (joint swelling) has become detectable at physical examination. Importantly, at this time, the immune processes have already matured, chronicity is established, and patients require long-standing treatment with disease-modifying anti-rheumatic drugs. The TREAT EARLIER trial studies the hypothesis that intervention in the symptomatic phase preceding clinical arthritis is more often successful in permanent disease modification because of less matured underlying disease processes. A two-level definition to identify patients that are prone to develop RA is used. First, patients should have CSA and recent-onset arthralgia (&lt; 1 year) that is suspect to progress to RA according to the expertise of the treating rheumatologist. Second, patients need to have subclinical inflammation of the hand or foot joints at 1.5 T MRI. The trial aims to recruit 230 participants from secondary care hospital settings across the south-west region of The Netherlands. Intervention will be randomly assigned and includes a single-dose of intramuscular 120 mg methylprednisolon followed by methotrexate (increasing dose to 25 mg/week orally) or placebo (both; injection and tablets) over the course of 1 year. Thereafter, participants are followed for another year. The primary endpoint is the development of clinically detectable arthritis, either fulfilling the 2010 criteria for RA or unclassified clinical arthritis of ≥ 2 joints, which persists for at least 2 weeks. DMARD-free status is a co-primary endpoint. The patient-reported outcomes functioning, along with workability and symptoms, are key secondary endpoints. Participants, caregivers (including those assessing the endpoints), and scientific staff are all blinded to the group assignment. This proof-of-concept study is the logical consequence of pre-work on the identification of patients with CSA with MRI-detected subclinical joint inflammation. It will test the hypothesis whether intervention in patients in this early phase with the cornerstone treatment of classified RA (methotrexate) hampers the development of persistent RA and reduce the disease burden of RA. Dutch Trial Register NL4599 (NTR4853). Registered on 20 October 2014
         datePublished:2020-10-16T00:00:00Z
         dateModified:2020-10-16T00:00:00Z
         pageStart:1
         pageEnd:18
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s13063-020-04731-2
         keywords:
            Rheumatoid arthritis
            Clinically suspect arthralgia
            Subclinical inflammation
            MRI
            Intervention
            Prevention
            Methotrexate
            Double-blind
            Placebo-controlled
            Randomized
            Medicine/Public Health
            general
            Biomedicine
            Statistics for Life Sciences
            Medicine
            Health Sciences
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13063-020-04731-2/MediaObjects/13063_2020_4731_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13063-020-04731-2/MediaObjects/13063_2020_4731_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13063-020-04731-2/MediaObjects/13063_2020_4731_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13063-020-04731-2/MediaObjects/13063_2020_4731_Fig4_HTML.png
         isPartOf:
            name:Trials
            issn:
               1745-6215
            volumeNumber:21
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ellis Niemantsverdriet
               url:http://orcid.org/0000-0002-5781-3817
               affiliation:
                     name:Leiden University Medical Center
                     address:
                        name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Yousra J. Dakkak
               affiliation:
                     name:Leiden University Medical Center
                     address:
                        name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Leonie E. Burgers
               affiliation:
                     name:Leiden University Medical Center
                     address:
                        name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Femke Bonte-Mineur
               affiliation:
                     name:Maasstad Hospital
                     address:
                        name:Department of Rheumatology, Maasstad Hospital, Rotterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gerda M. Steup-Beekman
               affiliation:
                     name:Haaglanden Medical Center – Bronovo
                     address:
                        name:Department of Rheumatology, Haaglanden Medical Center – Bronovo, The Hague, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sjoerd M. van der Kooij
               affiliation:
                     name:Haga Hospital
                     address:
                        name:Department of Rheumatology, Haga Hospital, The Hague, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hido D. Boom
               affiliation:
                     name:Spaarne Gasthuis
                     address:
                        name:Department of Rheumatology, Spaarne Gasthuis, Haarlem, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Cornelia F. Allaart
               affiliation:
                     name:Leiden University Medical Center
                     address:
                        name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Pascal H. P. de Jong
               affiliation:
                     name:Erasmus Medical Center
                     address:
                        name:Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Annette H. M. van der Helm-van Mil
               affiliation:
                     name:Leiden University Medical Center
                     address:
                        name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
                        type:PostalAddress
                     type:Organization
                     name:Erasmus Medical Center
                     address:
                        name:Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:TREAT Early Arthralgia to Reverse or Limit Impending Exacerbation to Rheumatoid arthritis (TREAT EARLIER): a randomized, double-blind, placebo-controlled clinical trial protocol
      description:We present a study protocol for a randomized, double-blind, placebo-controlled trial that investigates the hypothesis if intervention in the symptomatic phase preceding clinical arthritis (clinically suspect arthralgia (CSA)) is effective in preventing progression from subclinical inflammation to clinically apparent persistent arthritis. Currently, rheumatoid arthritis (RA) can be recognized and diagnosed when arthritis (joint swelling) has become detectable at physical examination. Importantly, at this time, the immune processes have already matured, chronicity is established, and patients require long-standing treatment with disease-modifying anti-rheumatic drugs. The TREAT EARLIER trial studies the hypothesis that intervention in the symptomatic phase preceding clinical arthritis is more often successful in permanent disease modification because of less matured underlying disease processes. A two-level definition to identify patients that are prone to develop RA is used. First, patients should have CSA and recent-onset arthralgia (&lt; 1 year) that is suspect to progress to RA according to the expertise of the treating rheumatologist. Second, patients need to have subclinical inflammation of the hand or foot joints at 1.5 T MRI. The trial aims to recruit 230 participants from secondary care hospital settings across the south-west region of The Netherlands. Intervention will be randomly assigned and includes a single-dose of intramuscular 120 mg methylprednisolon followed by methotrexate (increasing dose to 25 mg/week orally) or placebo (both; injection and tablets) over the course of 1 year. Thereafter, participants are followed for another year. The primary endpoint is the development of clinically detectable arthritis, either fulfilling the 2010 criteria for RA or unclassified clinical arthritis of ≥ 2 joints, which persists for at least 2 weeks. DMARD-free status is a co-primary endpoint. The patient-reported outcomes functioning, along with workability and symptoms, are key secondary endpoints. Participants, caregivers (including those assessing the endpoints), and scientific staff are all blinded to the group assignment. This proof-of-concept study is the logical consequence of pre-work on the identification of patients with CSA with MRI-detected subclinical joint inflammation. It will test the hypothesis whether intervention in patients in this early phase with the cornerstone treatment of classified RA (methotrexate) hampers the development of persistent RA and reduce the disease burden of RA. Dutch Trial Register NL4599 (NTR4853). Registered on 20 October 2014
      datePublished:2020-10-16T00:00:00Z
      dateModified:2020-10-16T00:00:00Z
      pageStart:1
      pageEnd:18
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s13063-020-04731-2
      keywords:
         Rheumatoid arthritis
         Clinically suspect arthralgia
         Subclinical inflammation
         MRI
         Intervention
         Prevention
         Methotrexate
         Double-blind
         Placebo-controlled
         Randomized
         Medicine/Public Health
         general
         Biomedicine
         Statistics for Life Sciences
         Medicine
         Health Sciences
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13063-020-04731-2/MediaObjects/13063_2020_4731_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13063-020-04731-2/MediaObjects/13063_2020_4731_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13063-020-04731-2/MediaObjects/13063_2020_4731_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13063-020-04731-2/MediaObjects/13063_2020_4731_Fig4_HTML.png
      isPartOf:
         name:Trials
         issn:
            1745-6215
         volumeNumber:21
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ellis Niemantsverdriet
            url:http://orcid.org/0000-0002-5781-3817
            affiliation:
                  name:Leiden University Medical Center
                  address:
                     name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Yousra J. Dakkak
            affiliation:
                  name:Leiden University Medical Center
                  address:
                     name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Leonie E. Burgers
            affiliation:
                  name:Leiden University Medical Center
                  address:
                     name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Femke Bonte-Mineur
            affiliation:
                  name:Maasstad Hospital
                  address:
                     name:Department of Rheumatology, Maasstad Hospital, Rotterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gerda M. Steup-Beekman
            affiliation:
                  name:Haaglanden Medical Center – Bronovo
                  address:
                     name:Department of Rheumatology, Haaglanden Medical Center – Bronovo, The Hague, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sjoerd M. van der Kooij
            affiliation:
                  name:Haga Hospital
                  address:
                     name:Department of Rheumatology, Haga Hospital, The Hague, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hido D. Boom
            affiliation:
                  name:Spaarne Gasthuis
                  address:
                     name:Department of Rheumatology, Spaarne Gasthuis, Haarlem, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Cornelia F. Allaart
            affiliation:
                  name:Leiden University Medical Center
                  address:
                     name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Pascal H. P. de Jong
            affiliation:
                  name:Erasmus Medical Center
                  address:
                     name:Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Annette H. M. van der Helm-van Mil
            affiliation:
                  name:Leiden University Medical Center
                  address:
                     name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
                     type:PostalAddress
                  type:Organization
                  name:Erasmus Medical Center
                  address:
                     name:Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Trials
      issn:
         1745-6215
      volumeNumber:21
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Leiden University Medical Center
      address:
         name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
         type:PostalAddress
      name:Leiden University Medical Center
      address:
         name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
         type:PostalAddress
      name:Leiden University Medical Center
      address:
         name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
         type:PostalAddress
      name:Maasstad Hospital
      address:
         name:Department of Rheumatology, Maasstad Hospital, Rotterdam, The Netherlands
         type:PostalAddress
      name:Haaglanden Medical Center – Bronovo
      address:
         name:Department of Rheumatology, Haaglanden Medical Center – Bronovo, The Hague, The Netherlands
         type:PostalAddress
      name:Haga Hospital
      address:
         name:Department of Rheumatology, Haga Hospital, The Hague, The Netherlands
         type:PostalAddress
      name:Spaarne Gasthuis
      address:
         name:Department of Rheumatology, Spaarne Gasthuis, Haarlem, The Netherlands
         type:PostalAddress
      name:Leiden University Medical Center
      address:
         name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
         type:PostalAddress
      name:Erasmus Medical Center
      address:
         name:Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands
         type:PostalAddress
      name:Leiden University Medical Center
      address:
         name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
         type:PostalAddress
      name:Erasmus Medical Center
      address:
         name:Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ellis Niemantsverdriet
      url:http://orcid.org/0000-0002-5781-3817
      affiliation:
            name:Leiden University Medical Center
            address:
               name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Yousra J. Dakkak
      affiliation:
            name:Leiden University Medical Center
            address:
               name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
               type:PostalAddress
            type:Organization
      name:Leonie E. Burgers
      affiliation:
            name:Leiden University Medical Center
            address:
               name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
               type:PostalAddress
            type:Organization
      name:Femke Bonte-Mineur
      affiliation:
            name:Maasstad Hospital
            address:
               name:Department of Rheumatology, Maasstad Hospital, Rotterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Gerda M. Steup-Beekman
      affiliation:
            name:Haaglanden Medical Center – Bronovo
            address:
               name:Department of Rheumatology, Haaglanden Medical Center – Bronovo, The Hague, The Netherlands
               type:PostalAddress
            type:Organization
      name:Sjoerd M. van der Kooij
      affiliation:
            name:Haga Hospital
            address:
               name:Department of Rheumatology, Haga Hospital, The Hague, The Netherlands
               type:PostalAddress
            type:Organization
      name:Hido D. Boom
      affiliation:
            name:Spaarne Gasthuis
            address:
               name:Department of Rheumatology, Spaarne Gasthuis, Haarlem, The Netherlands
               type:PostalAddress
            type:Organization
      name:Cornelia F. Allaart
      affiliation:
            name:Leiden University Medical Center
            address:
               name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
               type:PostalAddress
            type:Organization
      name:Pascal H. P. de Jong
      affiliation:
            name:Erasmus Medical Center
            address:
               name:Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands
               type:PostalAddress
            type:Organization
      name:Annette H. M. van der Helm-van Mil
      affiliation:
            name:Leiden University Medical Center
            address:
               name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
               type:PostalAddress
            type:Organization
            name:Erasmus Medical Center
            address:
               name:Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
      name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
      name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
      name:Department of Rheumatology, Maasstad Hospital, Rotterdam, The Netherlands
      name:Department of Rheumatology, Haaglanden Medical Center – Bronovo, The Hague, The Netherlands
      name:Department of Rheumatology, Haga Hospital, The Hague, The Netherlands
      name:Department of Rheumatology, Spaarne Gasthuis, Haarlem, The Netherlands
      name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
      name:Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands
      name:Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
      name:Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands

External Links {🔗}(214)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

5.33s.